The efficacy of 0.05% cyclosporin eye drop for dry eye disease

Clinical efficacy of cyclosporin 0.05% for Treatment of Dry Eye with Meibomian Gland Dysfunction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0006923

Enrollment

Registered

2022-01-13

Start date

2015-12-01

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The subjects assigned to Group 1 were treated with preservative-free 0.1% sodium hyaluronate eye drops (Hyal Q®, Il-Dong Inc, Korea) four times daily and 0.05% topical cyclosporine eye drops (R

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age over 19 years of age with dry eye syndorome with meibomian gland dysfunction. The subjects were those who voluntarily agreed to participate in this study through the clinical trial recruitment notice of our hospital.

Exclusion criteria

Exclusion criteria: Patients with ocular surface disease, previous ocular surgery, glaucoma, contact lens use, and systemic immune-related disease, receiving cyclosporine treatment for more than a year, and pregnant and lactating women were excluded from the study.

Design outcomes

Primary

Measure	Time frame
Lid margin telangiectasia, Meibomian gland secretion, Conjunctival injection, Corneal staining, Tear break-up time, Lipid layer thickness	—

Secondary

Measure	Time frame
Ocular Surface Disease Index questionnaire (ocular irritation, ocular pain, glare, decreased visual acuity)	—

Countries

Korea, Republic of

Contacts

Public ContactYeonji Jo

Pusan National University Hospital

jo.yeonji@gmail.com+82-51-240-7326

Outcome results